Presence of GAD65 Autoantibodies in the Serum of Children with Autism or ADHD

Overview

Journal Eur Child Adolesc Psychiatry

Specialties Pediatrics
Psychiatry

Date 2012 Feb 11

PMID 22323074

Citations 28

Authors

Ujjwal K Rout

Nils K Mungan

Dirk M Dhossche

Affiliations

Soon will be listed here.

Abstract

Antibodies against glutamic acid decarboxylase 65 (GAD65) have been detected in the serum of patients with several neurological disorders. The presence of antibodies against GAD65 has not yet been examined in the serum of patients with neurodevelopmental disorders such as autism or attention-deficit/hyperactivity disorder (ADHD). In this study, GAD65 antibodies and total IgG were assayed in the serum of normal subjects and patients diagnosed with autism or ADHD. GAD65 antibodies were detected in the serum of 15% of children with autism (N = 20), 27% of children with ADHD (N = 15) and of none of the controls (N = 14). The serum of 60% of autistic and 53% of ADHD patients reacted with Purkinje neurons in mouse cerebellum. Serum from 20% of ADHD patients reacted also with the cells in the molecular and granule cell layers and cells in the vicinity of the Purkinje neurons. No association was found between the titer of GAD65 antibodies and total IgG levels, and presence of seizures or mental retardation. None of the ADHD patients were diagnosed with mental retardation. Serum anti-GAD65 antibodies may be a common marker of subgroups of patients with autism and ADHD. Reactions of serum antibodies with the cells in the cerebellum in these patients suggest direct effects on brain function. The subgroup of children with autism and ADHD that tests positive for GAD65 antibodies needs further characterization in a larger study.

Citing Articles

Impaired striatal glutamate/GABA regulation in violent offenders with antisocial personality disorder and psychopathy.

Tully J, Pereira A, Sethi A, Griem J, Cross B, Williams S Mol Psychiatry. 2024; 29(6):1824-1832.

PMID: 38326560 PMC: 11371654. DOI: 10.1038/s41380-024-02437-4.

Catecholaminergic and cholinergic neuromodulation in autism spectrum disorder: A comparison to attention-deficit hyperactivity disorder.

Koevoet D, Deschamps P, Kenemans J Front Neurosci. 2023; 16:1078586.

PMID: 36685234 PMC: 9853424. DOI: 10.3389/fnins.2022.1078586.

Association between type 1 diabetes and neurodevelopmental disorders in children and adolescents: A systematic review and meta-analysis.

Xie X, Lei X, Xiao C, Li Y, Lei X Front Psychiatry. 2022; 13:982696.

PMID: 36483136 PMC: 9722754. DOI: 10.3389/fpsyt.2022.982696.

Orexin/Hypocretin System Dysfunction in ESSENCE (Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations).

Knez R, Stevanovic D, Fernell E, Gillberg C Neuropsychiatr Dis Treat. 2022; 18:2683-2702.

PMID: 36411777 PMC: 9675327. DOI: 10.2147/NDT.S358373.

Back to the Future: The Role of Infections in Psychopathology. Focus on OCD.

Della Vecchia A, Marazziti D Clin Neuropsychiatry. 2022; 19(4):248-263.

PMID: 36101642 PMC: 9442856. DOI: 10.36131/cnfioritieditore20220407.

References

Perlov E, Tebarzt van Elst L, Buechert M, Maier S, Matthies S, Ebert D . H¹-MR-spectroscopy of cerebellum in adult attention deficit/hyperactivity disorder. J Psychiatr Res. 2010; 44(14):938-43. DOI: 10.1016/j.jpsychires.2010.02.016. View

Fatemi S, Halt A, Stary J, Kanodia R, Schulz S, Realmuto G . Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry. 2002; 52(8):805-10. DOI: 10.1016/s0006-3223(02)01430-0. View

Mitoma H, Ishida K, Shizuka-Ikeda M, Mizusawa H . Dual impairment of GABAA- and GABAB-receptor-mediated synaptic responses by autoantibodies to glutamic acid decarboxylase. J Neurol Sci. 2003; 208(1-2):51-6. DOI: 10.1016/s0022-510x(02)00423-9. View

Yip J, Soghomonian J, Blatt G . Decreased GAD65 mRNA levels in select subpopulations of neurons in the cerebellar dentate nuclei in autism: an in situ hybridization study. Autism Res. 2009; 2(1):50-9. PMC: 2724747. DOI: 10.1002/aur.62. View

Wenthold R, Skaggs K, Reale R . Retrograde axonal transport of antibodies to synaptic membrane components. Brain Res. 1984; 304(1):162-5. DOI: 10.1016/0006-8993(84)90874-6. View

Lees G, Horsburgh R . Retrograde transport of dopamine beta-hydroxylase antibodies in sympathetic neurons: effects of drugs modifying noradrenergic transmission. Brain Res. 1984; 301(2):281-6. DOI: 10.1016/0006-8993(84)91097-7. View

Sokol D, McIntyre J, Wagenknecht D, Dropcho E, Patel H, Salanova V . Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy. Neurology. 2004; 62(3):517-8. DOI: 10.1212/01.wnl.0000106821.83436.59. View

Tanaka S, Matsunaga H, Kimura M, Tatsumi K, Hidaka Y, Takano T . Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol. 2003; 141(1-2):155-64. DOI: 10.1016/s0165-5728(03)00252-2. View

Rout U, Dhossche D . A pathogenetic model of autism involving Purkinje cell loss through anti-GAD antibodies. Med Hypotheses. 2008; 71(2):218-21. DOI: 10.1016/j.mehy.2007.11.012. View

10.

Alarcon-Segovia D, Ruiz-Arguelles A, Llorente L . Broken dogma: penetration of autoantibodies into living cells. Immunol Today. 1996; 17(4):163-4. DOI: 10.1016/s0167-5699(96)90258-3. View

11.

Friden P, Olson T, Obar R, Walus L, Putney S . Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor. J Pharmacol Exp Ther. 1996; 278(3):1491-8. View

12.

Bauman M, Kemper T . The neuropathology of the autism spectrum disorders: what have we learned?. Novartis Found Symp. 2003; 251:112-22. View

13.

Ronald A, Simonoff E, Kuntsi J, Asherson P, Plomin R . Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. J Child Psychol Psychiatry. 2008; 49(5):535-42. DOI: 10.1111/j.1469-7610.2007.01857.x. View

14.

Kaplitt M, Feigin A, Tang C, Fitzsimons H, Mattis P, Lawlor P . Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007; 369(9579):2097-105. DOI: 10.1016/S0140-6736(07)60982-9. View

15.

Soliva J, Moreno A, Fauquet J, Bielsa A, Carmona S, Gispert J . Cerebellar neurometabolite abnormalities in pediatric attention/deficit hyperactivity disorder: a proton MR spectroscopic study. Neurosci Lett. 2009; 470(1):60-4. DOI: 10.1016/j.neulet.2009.12.056. View

16.

Rommelse N, Franke B, Geurts H, Hartman C, Buitelaar J . Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. Eur Child Adolesc Psychiatry. 2010; 19(3):281-95. PMC: 2839489. DOI: 10.1007/s00787-010-0092-x. View

17.

Ishida K, Mitoma H, Mizusawa H . Reversibility of cerebellar GABAergic synapse impairment induced by anti-glutamic acid decarboxylase autoantibodies. J Neurol Sci. 2008; 271(1-2):186-90. DOI: 10.1016/j.jns.2008.04.019. View

18.

Banks W, Farr S, Morley J, Wolf K, Geylis V, Steinitz M . Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. Exp Neurol. 2007; 206(2):248-56. PMC: 2080786. DOI: 10.1016/j.expneurol.2007.05.005. View

19.

Mackie S, Shaw P, Lenroot R, Pierson R, Greenstein D, Nugent 3rd T . Cerebellar development and clinical outcome in attention deficit hyperactivity disorder. Am J Psychiatry. 2007; 164(4):647-55. DOI: 10.1176/ajp.2007.164.4.647. View

20.

Lichtenstein P, Carlstrom E, Rastam M, Gillberg C, Anckarsater H . The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry. 2010; 167(11):1357-63. DOI: 10.1176/appi.ajp.2010.10020223. View